After their Phase 2 trial issues, the price sank like titanic.
It may be the lowest price and it may be a good opportunity to go long.
Analyst predictions for the company goes as high as $28.
It may be the lowest price and it may be a good opportunity to go long.
Analyst predictions for the company goes as high as $28.
Related Ideas
ADVR update
trader_tolga
about ADVM
About my point about Phase 2 trial issue, any biopharma company has the risk of a failed Phase 2 trials and/or side-effects. That is why they do these trials, not immediately distribute to public. I am optimistic with the company's vision.